Localization of mesothelin in epithelial ovarian cancer.
about
Mesothelin targeted cancer immunotherapyClinical impacts of mesothelin expression in gastrointestinal carcinomasRecognition of Mesothelin by the Therapeutic Antibody MORAb-009: STRUCTURAL AND MECHANISTIC INSIGHTSAdvances in anticancer immunotoxin therapyA novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity.Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.Mesothelin Immunotherapy for Cancer: Ready for Prime Time?Plasma Mesothelin as a Novel Diagnostic and Prognostic Biomarker in Colorectal Cancer.Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers.Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesotheliomaPhase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.Past, present and future targets for immunotherapy in ovarian cancerNovel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice.Chemotherapy and targeted therapies for unresectable malignant mesotheliomaImportance of luminal membrane mesothelin expression in intraductal papillary mucinous neoplasms.The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors.Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicityPhase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors.A novel PET imaging using ⁶⁴Cu-labeled monoclonal antibody against mesothelin commonly expressed on cancer cellsSafety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging.Incorporation of porcine adenovirus 4 fiber protein enhances infectivity of adenovirus vector on dendritic cells: implications for immune-mediated cancer therapy.A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune inductionHigh mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptorMesothelin-targeted agents in clinical trials and in preclinical development.Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancerRecent Advances in the Development of Antineoplastic Agents Derived from Natural ProductsRecombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors.Early detection biomarkers for ovarian cancer.Immunogenicity of therapeutic recombinant immunotoxins.The role of mesothelin in tumor progression and targeted therapy.Murine mesothelin: characterization, expression, and inhibition of tumor growth in a murine model of pancreatic cancer.Mesothelin regulates growth and apoptosis in pancreatic cancer cells through p53-dependent and -independent signal pathwayConventional and proteomic technologies for the detection of early stage malignancies: markers for ovarian cancer.Mesothelin Expression in Advanced Gastroesophageal Cancer Represents a Novel Target for Immunotherapy.Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer.Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.
P2860
Q24656242-089841F5-1D21-4656-B51E-5848CE57620FQ26748680-EC1FAAB8-3FEC-4C0C-BEA6-DA9612CA1008Q27670713-1C7555FE-5BA1-455D-B02A-8810327B60B4Q28085551-60C1DC3A-20E7-4BF0-A700-C0B4D844BF15Q30478956-D71FFF8D-4B75-4F41-A987-079783D8090DQ33357295-AD153F2D-DFED-4234-BF4A-89BEFD23F471Q33688809-EC4665A2-7F12-4CCE-9D06-7EE7E1A215EAQ33816551-95519EDD-F9AB-46BB-8C20-99F62B524B08Q33820839-6996A450-C980-4D06-B742-4FACBB0E95EDQ33828838-F68085D4-2B2F-4236-A4DF-AECD0581BC82Q34111770-86379A21-489F-4A7D-B7A7-D508F72FFC8CQ34459015-F9772573-9996-459E-83CC-F3E12DAE6414Q34614847-125C6AC1-0A44-48A7-A5F5-B4601640B4EAQ34676443-8DD6396E-8CE6-4874-9580-FCE001BEAFEAQ35034010-D7BBD3EE-66CC-4976-908F-BAF4B20B1D6AQ35049589-91B2B109-BC23-4BD8-8B1B-CC6FE9C649B7Q35141369-4AA933C2-1430-44DA-9037-A5BB0E7826EEQ35167481-050EE6CB-322E-4E37-B1E2-5BD46B880BAEQ35185032-974D92E4-4DA5-4C9C-A4C2-1FEB0E72CA4DQ35189855-51855ECD-2EA8-4950-92AC-C6DCF436D903Q35288837-1613B234-EBC1-41E0-AE04-2BBE5683BE85Q35323396-2C46D273-7758-4D7D-96FE-2401AE1BE225Q35552059-86386B82-DB27-42A3-8FC0-ECB43B36E304Q35620238-7533948C-03AB-4195-B23F-D4F09BDA4DDEQ35787391-929E35C5-86EF-4CC3-9FDE-A9EC92C721BEQ35793906-A5D08C5F-938F-4645-B088-7F5E1366817FQ35802193-4E49DE47-B876-4511-9CFC-59D314ACA458Q35815380-9B1CAFE7-E0B9-4927-AEA7-4CE140FD0458Q36075289-BA2F1516-0F28-45B5-8C04-6D27DD55D0E3Q36273796-F608F76E-DB9E-4CE3-AA73-447F76039E69Q36359728-D3F5F36E-952C-4959-A0F3-4BF985BEF5F7Q36520143-B04DC5E7-442A-4E04-ACD7-197FE519FE1CQ36593468-81FFE2E2-4349-4121-BEE3-2D12133FC6F4Q36597831-A487E55D-FFE9-4ADE-A13D-A7EDF4B3FD0FQ36639456-65124F1B-0D78-4CE4-BAD0-6CA4A9E40B49Q36649265-B837C549-91A1-4B5E-AB59-04233099F744Q36686826-09AED64C-53CF-4951-8BE7-26C2E649CCE1Q36767781-686ACAFA-A2E9-4382-810F-792E88F0EF94Q36976473-98731280-B6DA-45EF-B650-6149E828A468Q37327375-6DDA739A-9AD3-4073-8617-7DE0DB74B735
P2860
Localization of mesothelin in epithelial ovarian cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Localization of mesothelin in epithelial ovarian cancer.
@en
type
label
Localization of mesothelin in epithelial ovarian cancer.
@en
prefLabel
Localization of mesothelin in epithelial ovarian cancer.
@en
P2093
P1476
Localization of mesothelin in epithelial ovarian cancer.
@en
P2093
Ira Pastan
Mark C Willingham
Raffit Hassan
Robert J Kreitman
P304
P356
10.1097/01.PAI.00000141545.36485.D6
P577
2005-09-01T00:00:00Z